Sun Pharma Adv. Res
Ticker > Company >

Sun Pharma Adv. Res share price

Sun Pharma Advanced Research Company Ltd.

NSE: SPARC BSE: 532872 SECTOR: Business Support  1.33 L   221   24

149.40
-0.05 (-0.03%)
BSE: 01 Aug 04:01 PM

Price Summary

Today's High

₹ 153.75

Today's Low

₹ 149

52 Week High

₹ 240.95

52 Week Low

₹ 109.2

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationAttractive
The stock is considerably attractive based on intrinsic value.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 4848.35 Cr.

Enterprise Value

₹ 5105.35 Cr.

No. of Shares

32.45 Cr.

P/E

0

P/B

0

Face Value

₹ 1

Div. Yield

0 %

Book Value (TTM)

₹  -6.8

CASH

₹ 1.19 Cr.

DEBT

₹ 258.19 Cr.

Promoter Holding

65.67 %

EPS (TTM)

₹  -10.64

Sales Growth

-5%

ROE

0 %

ROCE

-321.18%

Profit Growth

11.05 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-5%
3 Year-19.44%
5 Year-1.35%

Profit Growth

1 Year11.05%
3 Year-32.86%
5 Year-2.2%

ROE%

1 Year0%
3 Year-88.49%
5 Year-53.09%

ROCE %

1 Year-321.18%
3 Year-167.84%
5 Year-196.64%

Debt/Equity

-1.1703

Price to Cash Flow

-13.38

Interest Cover Ratio

-37.7642

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 65.67 0.00
Mar 2025 65.67 0.00
Dec 2024 65.67 0.00
Sep 2024 65.67 2.78
Jun 2024 65.67 2.78
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has an efficient Cash Conversion Cycle of 80.3274 days.
  • The company has a high promoter holding of 65.67%.

 Limitations

  • The company has shown a poor profit growth of -32.8561429198562% for the Past 3 years.
  • The company has shown a poor revenue growth of -19.4366417301319% for the Past 3 years.
  • Company has a poor ROE of -88.4851666666667% over the past 3 years.
  • Company has a poor ROCE of -167.8379% over the past 3 years
  • Company has negative cash flow from operations of -362.409.
  • The company has a low EBITDA margin of -253.92156% over the past 5 years.
  • The company has negative book value.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
Net Sales 16.56 16.81 12.86 14.91 27.19
Total Expenditure 124.08 111.93 116.71 89.29 81.11
Operating Profit -107.52 -95.12 -103.85 -74.38 -53.92
Other Income 4.4 1.56 0.04 0.19 0
Interest 0.88 0.52 1.11 2.77 4.51
Depreciation 2.69 2.76 2.77 2.75 2.55
Exceptional Items 0 0 0 0 0
Profit Before Tax -106.69 -96.84 -107.69 -79.71 -60.98
Tax 0 0 0 0 0
Profit After Tax -106.69 -96.84 -107.69 -79.71 -60.98
Adjusted EPS (Rs) -3.29 -2.98 -3.32 -2.46 -1.88

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 252.96 137.25 238.78 75.55 71.77
Total Expenditure 387.93 324 452.84 479.34 399.04
Operating Profit -134.98 -186.75 -214.06 -403.79 -327.28
Other Income 5.41 6.84 10.88 29.47 1.79
Interest 10.65 13.33 7.63 1.66 8.91
Depreciation 10.92 10.16 11.77 12.13 10.83
Exceptional Items 0 0 0 0 0
Profit Before Tax -151.14 -203.4 -222.58 -388.11 -345.22
Tax 0 0 0 0 0
Net Profit -151.14 -203.4 -222.58 -388.11 -345.22
Adjusted EPS (Rs.) -5.77 -7.48 -6.86 -11.96 -10.64

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 26.21 27.19 32.45 32.45 32.45
Total Reserves -194.46 4.04 480.32 92.4 -253.07
Borrowings 112.5 0 0 0 100
Other N/C liabilities 52.09 77.43 138.41 117.59 76.17
Current liabilities 233.35 171.43 178.95 243.89 373.72
Total Liabilities 229.69 280.08 830.13 486.33 329.28
Assets
Net Block 90.56 91.87 105.75 102.65 95.33
Capital WIP 5.23 3.72 1.87 1.27 0.56
Intangible WIP 0 22.65 25.13 42.53 53.59
Investments 0 0 0 0.42 0.42
Loans & Advances 70.64 67.83 64.8 67.67 128.19
Other N/C Assets 3.46 22.87 177.61 25.4 25.93
Current Assets 59.8 71.15 454.96 246.41 25.26
Total Assets 229.69 280.08 830.13 486.33 329.28
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations -151.14 -203.4 -222.58 -388.11 -345.22
Adjustment 48.75 16.67 6.99 -11.33 18.83
Changes in Assets & Liabilities -47.88 -26.05 141.11 -25.88 -46.8
Tax Paid -1.63 4.54 5.37 -4.11 10.79
Operating Cash Flow -151.9 -208.23 -69.12 -429.43 -362.41
Investing Cash Flow 1.56 -29.17 -548.28 391.11 157.66
Financing Cash Flow 159.28 229.32 616.76 42.8 200.88
Net Cash Flow 8.95 -8.08 -0.64 4.48 -3.87

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 65.67 65.67 65.67 65.67 65.67
aalok dilip shanghvi 0.11 0.11 0.11 0.11 0.11
aditya medisales limited 1.51 1.51 1.51 1.51 1.51
dilip.s.shanghvi - - - 19.05 19.05
kumud shantilal shanghvi - - - 0.01 0.01
raksha sudhir valia - - - 1.28 1.28
shanghvi family & friends... - - - 0.05 0.05
shanghvi finance private ... - - - 42.28 42.28
sudhir vrundavandas valia... - - - 0.57 0.57
unimed investments limite... 0.39 0.39 0.39 0.39 0.39
vibha dilip shanghvi 0.33 0.33 0.33 0.33 0.33
vidhi dilip shanghvi 0.11 0.11 0.11 0.11 0.11
dilip shantilal shanghvi 19.05 19.05 19.05 - -
kumud s. shanghvi 0.01 0.01 0.01 - -
raksha s.valia 1.28 1.28 1.28 - -
shanghvi family & friends... 0.05 0.05 0.05 - -
shanghvi finance private ... 42.28 42.28 42.28 - -
sudhir valia 0.57 0.57 0.57 - -
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 34.33 34.33 34.33 34.33 34.33
enam holdings pvt ltd - - - 1.04 1.04
lakshdeep investments & f... 1.86 1.86 1.86 1.86 1.86
llp - - - 0.29 0.25
paresh mohanlal parekh 1.12 1.12 1.12 1.12 1.12
sun pharmaceutical indust... 3.18 3.18 3.18 3.18 3.18
vijay mohanlal parekh 1.13 1.13 1.13 1.13 1.13
enam securities private l... 1.04 1.04 1.04 - -
rekha jhunjhunwala - - 1.59 - -
jhunjhunwala rekha rakesh... 1.94 1.94 - - -

Annual Reports

Title Link
Title Link
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit ACUITE RATINGS
TYPE AGENCY Link
TYPE AGENCY Link
Research BOB Capital Market

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q3FY22
Concall Q2FY25
Concall Q2FY24
Concall Q2FY21
Concall Q2FY20
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q2FY25
Presentation Q2FY22
Presentation Q1FY21
Presentation Q1FY20
Presentation H1FY21

Company News

Sun Pharma Advanced Research Company submits board meeting intimation 28 Jul, 5:11 PM Sun Pharma Advanced Research Company informs about AGM 19 Jul, 2:40 PM Sun Pharma Advanced Research incorporates wholly owned subsidiary 7 Jul, 9:12 AM Sun Pharma Advanced Research Company informs about newspaper advertisement 21 May, 5:07 PM Sun Pharma Adv. Res - Quaterly Results 19 May, 8:33 PM Sun Pharma Adv. Res - Quaterly Results 19 May, 8:33 PM Sun Pharma Advanced Research Company informs about trading window closure 27 Mar, 4:51 PM Sun Pharma Adv. Res - Quaterly Results 10 Feb, 7:56 PM Sun Pharma Adv. Res - Quaterly Results 10 Feb, 7:56 PM SPARC inks binding LoI with UCSF, Tiller 17 Dec, 11:08 AM Sun Pharma Advanced Research Company informs about press release 17 Dec, 9:46 AM Sun Pharma Adv. Res - Quaterly Results 4 Nov, 2:59 PM Sun Pharma Adv. Res - Quaterly Results 4 Nov, 2:59 PM Sun Pharma Adv. Res - Quaterly Results 4 Nov, 2:59 PM Sun Pharma Advanced Research Company informs about outcome of board meeting 5 Aug, 5:25 PM Sun Pharma Adv. Res - Quaterly Results 5 Aug, 2:24 PM Sun Pharma Adv. Res - Quaterly Results 5 Aug, 2:24 PM Sun Pharma Adv. Res - Quaterly Results 5 Aug, 2:24 PM Sun Pharma Adv. Res - Quaterly Results 24 May, 8:26 PM Sun Pharma Adv. Res - Quaterly Results 24 May, 8:26 PM Sun Pharma Advanced Research Company informs about compliance certificate 10 Apr, 4:06 PM Sun Pharma Advanced Research Company informs about press release 10 Apr, 9:59 AM Sun Pharma Advanced Research Company informs about loss of share certificates 7 Mar, 1:15 PM Sun Pharma Adv. Res - Quaterly Results 5 Feb, 1:49 PM Sun Pharma Adv. Res - Quaterly Results 5 Feb, 1:49 PM Sun Pharma Adv. Res - Quaterly Results 5 Feb, 1:49 PM Sun Pharma Advanced Research Company informs about clarification on price movement 4 Jan, 4:55 PM Sun Pharma Advanced Research Company informs about statement on deviation or variation 6 Nov, 5:14 PM Sun Pharma Adv. Res - Quaterly Results 6 Nov, 3:22 PM Sun Pharma Adv. Res - Quaterly Results 6 Nov, 3:22 PM Sun Pharma Adv. Res - Quaterly Results 6 Nov, 3:22 PM SPARC enters into agreement for SCD-153 with JHU and IOCB 2 Nov, 9:52 AM Sun Pharma Advanced Research Company informs about press release 30 Oct, 9:58 AM Sun Pharma Advanced Research Company informs about press release 19 Oct, 12:42 PM Sun Pharma Advanced Research Company informs about loss of share certificates 10 Oct, 5:17 PM Sun Pharma Advanced Research Company informs about details of loss of certificate 9 Oct, 5:08 PM SPARC incorporates wholly owned subsidiary in Delaware 26 Sep, 2:05 PM Sun Pharma Advanced Research Company informs about loss of share certificates 22 Sep, 12:54 PM Sun Pharma Adv. Res - Quaterly Results 7 Aug, 3:15 PM Sun Pharma Adv. Res - Quaterly Results 7 Aug, 3:15 PM Sun Pharma Adv. Res - Quaterly Results 7 Aug, 3:15 PM Sun Pharma Advanced Research Company informs about board meeting 29 Jul, 2:25 PM Sun Pharma Adv. Res - Quaterly Results 22 May, 1:39 PM Sun Pharma Adv. Res - Quaterly Results 22 May, 1:39 PM Sun Pharma Adv. Res - Quaterly Results 22 May, 1:39 PM Sun Pharma Advanced Research Company informs about details of loss of certificate 28 Apr, 1:00 PM Sun Pharma Advanced Research Company informs about loss of share certificates 18 Apr, 1:14 PM Sun Pharma Advanced Research Company informs about closure of trading window 30 Mar, 11:17 AM Sun Pharma Advanced Research Company informs about IT security incident 27 Mar, 9:26 AM Sun Pharma Advanced Research Company informs about issuance of duplicate share certificate 24 Feb, 4:50 PM

Sun Pharma Adv. Res Stock Price Analysis and Quick Research Report. Is Sun Pharma Adv. Res an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Sun Pharma Adv. Res stock price today is Rs 149.84. Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Sun Pharma Adv. Res . 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Sun Pharma Adv. Res has a PE ratio of -14.0854867972062 which is low and comparatively undervalued .

  • Share Price: - The current share price of Sun Pharma Adv. Res is Rs 149.84. One can use valuation calculators of ticker to know if Sun Pharma Adv. Res share price is undervalued or overvalued.

  • Return on Assets (ROA): - Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Sun Pharma Adv. Res has ROA of -84.6538 % which is a bad sign for future performance. (higher values are always desirable)

  • Current ratio: - The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Sun Pharma Adv. Res has a Current ratio of 0.0676 .

  • Return on equity: - ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Sun Pharma Adv. Res has a ROE of 0 % .(higher is better)

  • Debt to equity ratio: - It is a good metric to check out the capital structure along with its performance. Sun Pharma Adv. Res has a Debt to Equity ratio of -1.1703 which means that the company has low proportion of debt in its capital.

  • Sales growth: - Sun Pharma Adv. Res has reported revenue growth of -5.0027 % which is poor in relation to its growth and performance. 

  • Operating Margin: - This will tell you about the operational efficiency of the company. The operating margin of Sun Pharma Adv. Res for the current financial year is -456.033637098347 %.

  • Dividend Yield: - It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Sun Pharma Adv. Res is Rs 0 and the yield is 0 %.

  • Earnings Per Share: - It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Sun Pharma Adv. Res is Rs -10.6379 . The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Sun Pharma Adv. Res in Ticker for free. Also, one can get the intrinsic value of Sun Pharma Adv. Res by using Valuation Calculators, which are available with a Finology ONE subscription. 

Last Updated on:
Brief about Sun Pharma Adv. Res

Sun Pharma Advanced Research Company Ltd. Financials: Check Share price, Balance Sheet, Annual report and Quarterly Results for company analysis

Welcome to the Sun Pharma Advanced Research Company Ltd. stock analysis page, designed to provide long-term stock investors with in-depth analysis of the company's performance. As a leading pharmaceutical research and development company, Sun Pharma Advanced Research Company Ltd. has established itself as a dynamic organization dedicated to innovation and growth. In this comprehensive stock analysis, we will delve into various critical aspects of the company's financial performance and offer valuable insights for potential investors.

Sun Pharma Advanced Research Company Ltd. Share Price:

Sun Pharma Advanced Research Company Ltd.'s share price is a critical factor governing the company's long-term growth potential. Analyzing the movement of the company's share price over time and comparing its performance with industry peers is essential for long-term investors seeking potential investment opportunities. By utilizing our pre-built screening tools, investors can quickly analyze Sun Pharma Advanced Research Company Ltd.'s share price trends and make informed decisions about potential long-term investment opportunities. A stock's share price is determined by a range of factors such as market sentiment, financial performance, and general economic conditions.

Sun Pharma Advanced Research Company Ltd. Balance Sheet:

Analyzing Sun Pharma Advanced Research Company Ltd.'s balance sheet is fundamental to evaluating the company's overall financial health and growth potential. The balance sheet provides insights into the company's liquidity, debt levels, and current ratio. By utilizing our pre-built screening tools, investors can compare Sun Pharma Advanced Research Company Ltd.'s balance sheet with industry peers and evaluate potential investment opportunities for long-term growth.

Sun Pharma Advanced Research Company Ltd. Annual Report:

Sun Pharma Advanced Research Company Ltd.'s annual reports provide valuable information for long-term investors seeking a comprehensive understanding of the company's performance. Our website provides downloadable copies of Sun Pharma Advanced Research Company Ltd.'s annual reports, enabling investors to delve into the information provided and develop insights into potential investment opportunities. Additionally, we offer premium feature tools, such as DCF Analysis, BVPS Analysis, Earnings multiple approaches, and DuPont Analysis, which provide in-depth analysis for investors to make well-informed decisions about their long-term investment strategies.

Sun Pharma Advanced Research Company Ltd. Dividend:

For long-term stock investors seeking consistent returns, analyzing the dividend payout history of Sun Pharma Advanced Research Company Ltd. is essential. Assessing the consistency and growth potential of the company's dividend payouts is crucial. On our website, you can find information on Sun Pharma Advanced Research Company Ltd.'s dividend payouts, enabling analysis and comparison with industry peers. Our pre-built screening tools are designed to help investors identify potential investment opportunities and make informed decisions about their long-term investments.

Sun Pharma Advanced Research Company Ltd. Quarterly Results:

Analyzing Sun Pharma Advanced Research Company Ltd.'s quarterly results is critical for long-term investors seeking a comprehensive understanding of the company's performance over time. Our website offers quick access to detailed analysis of Sun Pharma Advanced Research Company Ltd.'s quarterly results, enabling investors to evaluate potential investment opportunities accurately. Additionally, we provide downloadable copies of Sun Pharma Advanced Research Company Ltd.'s quarterly reports on our website, allowing investors to perform in-depth analysis and gain valuable insights.

Sun Pharma Advanced Research Company Ltd. Stock Price:

Sun Pharma Advanced Research Company Ltd.'s stock price is a critical factor governing the company's long-term growth potential. Analyzing the trends in Sun Pharma Advanced Research Company Ltd.'s stock price over time and comparing its performance with industry peers is necessary for long-term investors seeking potential investment opportunities. Our website offers pre-built screening tools that enable quick analysis and identification of potential long-term investment opportunities, empowering investors to make well-informed decisions about their investment strategies. Our website provides pre-built screening tools to help investors analyze stock prices and performance.

Sun Pharma Advanced Research Company Ltd. Price Chart:

Graphical representation of Sun Pharma Advanced Research Company Ltd.'s stock price trends is highly beneficial for long-term investors seeking potential investment opportunities. By utilizing the price charts available on our website and combining them with our pre-built screening tools, investors can gain valuable insights into the company's performance and growth potential for long-term investments.

Sun Pharma Advanced Research Company Ltd. News:

Staying updated with the latest news and market developments is critical for long-term stock investors. Our website features timely articles and events related to Sun Pharma Advanced Research Company Ltd.'s stock market performance, enabling investors to stay up-to-date on the latest developments and make informed decisions about potential investment opportunities.

Sun Pharma Advanced Research Company Ltd. Concall Transcripts:

Analyzing Sun Pharma Advanced Research Company Ltd.'s con call transcripts provides long-term investors with critical insights into the company's future guidance, strategic initiatives, and financial performance. On our website, you can access Sun Pharma Advanced Research Company Ltd.'s con call transcripts as downloadable documents for in-depth analysis. Additionally, our premium feature tools, including DCF Analysis and Earnings multiple approaches, can help investors analyze the information provided in the transcripts and develop valuable insights for their long-term investment strategies.

Sun Pharma Advanced Research Company Ltd. Investor Presentations:

Sun Pharma Advanced Research Company Ltd.'s investor presentations offer a wealth of information for long-term investors interested in the company's growth potential. Our website provides downloadable copies of Sun Pharma Advanced Research Company Ltd.'s investor presentations, allowing investors to analyze detailed information and gain insights for long-term investment strategies. Utilizing our premium feature tools, such as BVPS Analysis and DuPont Analysis, investors can delve deeper into the information presented and make well-informed decisions.

Sun Pharma Advanced Research Company Ltd. Promoters and Shareholders:

Understanding the promoters and shareholders of Sun Pharma Advanced Research Company Ltd. is necessary for long-term investors. Our website provides detailed information about the company's promoters and shareholders, facilitating in-depth analysis and informed decision-making. By utilizing our pre-built screening tools, investors can analyze Sun Pharma Advanced Research Company Ltd.'s shareholding patterns and identify potential long-term growth opportunities. 

Sun Pharma Advanced Research Company's Share Capital Analysis

In the review period from March 2020 to March 2024, the Share Capital of Sun Pharma Advanced Research Company showcased a stable growth, initially remaining constant at Rs. 26.21 Cr., and experiencing a significant increase to Rs. 32.45 Cr. by March 2023, maintaining this level into March 2024.

Sun Pharma Advanced Research Company's Reserves and Surplus

The company's reserves took a dramatic turn, from a negative balance of Rs. 44.84 Cr. in March 2020 to a peak of Rs. 480.32 Cr. by March 2023, before adjusting to Rs. 92.40 Cr. in March 2024. This reflects a volatile yet improving financial strength.

Sun Pharma Advanced Research Company's Debt Profile

Borrowings saw a noteworthy spike at Rs. 112.50 Cr. by March 2021 but were completely phased out by March 2022, signaling a strategic move towards debt-free operations.

Sun Pharma Advanced Research Company's Assets Growth

The company's total assets experienced a significant rise, aligning with liabilities from Rs. 272.56 Cr. in March 2020 to a peak of Rs. 830.13 Cr. by March 2023, before adjusting to Rs. 486.33 Cr. in March 2024. Notably, the increase in Current Assets from Rs. 67.19 Cr. to Rs. 454.96 Cr. over the period indicates a substantial enhancement in liquidity.

This data is an analysis for the Standalone Balance Sheet of the company, offering insights into its financial health and operational efficiency over the observed period.

Investors looking into the pharma sector might also explore various market trends, including NSE/BSE indices movements, to make informed decisions.

Read More
X